Eupraxia Pharmaceuticals Announces Change of Auditor

About this update from Eupraxia Pharmaceuticals, Inc.

[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Change of Auditor\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n /NOT FOR DISSEMINATION IN\n \n THE UNITED STATES\n \n OR THROUGH U.S. NEWSWIRE SERVICES/\n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Sept. 7, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced today that the board of directors of the Company approved the appointment of KPMG LLP (\"KPMG\") as auditor of the Company, with such appointment being effective as of\n \n August 30, 2023\n \n . Concurrently, Baker Tilly WM, LLP (\"Baker Tilly\"), has resigned as the Company's auditor.\n \n \n In accordance with the requirements of National Instrument 51-102 – Continuous Disclosure Obligations (\"NI 51-102\"), a change of auditor notice and acknowledgement letters from Baker Tilly and KPMG have been filed under Eupraxia's profile on SEDAR+. There were no \"reportable events\" (within the meaning of NI 51-102) involving Baker Tilly.\n \n \n \n \n About Eupraxia Pharmaceuticals Inc.\n \n \n \n \n Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology that delivers targeted, long-lasting activity with fewer side effects.\n \n \n Eupraxia's lead product candidate, EP-104IAR, recently completed a Phase\n \n 2b\n \n clinical trial for the treatment of pain due to osteoarthritis of the knee. EP-104IAR met its primary endpoint and three of the four secondary endpoints. The EP-104 platform has expanded into gastrointestinal disease and has dosed patients in a Phase\n \n 1b\n \n /2a program to treat eosinophilic esophagitis. Eupraxia is also developing a pipeline of later and earlier stage long-act...

More updates from Eupraxia Pharmaceuticals, Inc.